Xanodyne Pharma Sells Lysteda, Refocuses on Pain Management
Xanodyne Pharmaceuticals Inc. has agreed to sell the global rights to Lysteda, a non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding, to Ferring Pharmaceuticals. No financial terms were disclosed for the deal, which Xanodyne says is part of a strategic refocusing on pain management drugs. Xanodyne has raised over $270 million in VC funding, including a $170 million Series A-1 round in 2005 that helped finance the $210 million acquisition of aaiPharma's pharmaceutical division out of bankruptcy. Backers include MPM Capital, AIG Investments, Aisling Capital, Blue Chip Venture Co., Essex Woodlands Health Ventures, HealthCare Ventures and Union Springs.
10 May 2010•4 mins read
